Trials / Unknown
UnknownNCT02617134
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-MUC1 CAR-T cells |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2017-11-01
- Completion
- 2018-11-01
- First posted
- 2015-11-30
- Last updated
- 2016-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02617134. Inclusion in this directory is not an endorsement.